Brain tumor MRI study pulled before it started
NCT ID NCT06648473
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 37 times
Summary
This study was designed to check how consistent MRI scans are in people with a slow-growing brain tumor (IDH1-mutant low-grade glioma) who are taking the drug ivosidenib. The goal was to improve how doctors measure tumor changes over time. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOW GRADE GLIOMA OF BRAIN are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.